Skip to main content

Table 2 Multivariate Cox model analysis for OS and PFS in the population

From: Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma

Variable

OS

PFS

HR (95%CI)

P value

HR (95%CI)

P value

ECOG performance

   

 0

Ref

 

Ref

 

 ≥ 1

2.556 (1.784–3.663)

0.021

1.570 (1.163–2.119)

0.003

Child Pugh

   

 A

Ref

 

Ref

 

 B

1.990 (1.385–2.860)

0.043

1.843 (1.334–2.547)

0.072

 C

2.339 (1.872–2.409)

0.037

1.992 (1.492–2.672)

0.069

AFP

   

 ≤ 400

Ref

 

Ref

 

 > 400

1.252 (1.152–1.309)

0.062

1.679 (1.253–1.998)

0.082

HBV

    

 No

Ref

 

Ref

 

 Yes

1.967 (1.032–2.843)

0.183

1.769 (1.265–2.018)

0.131

Macrovascular Invasion

   

 No

Ref

 

Ref

 

 Yes

1.742 (1.139–2.664)

0.010

2.982 (1.279–4.671)

0.006

Combined with target therapy

  

 Yes

Ref

 

Ref

 

 No

2.493 (2.019–3.052)

0.032

2.835 (2.182–3.461)

0.025

LIPI

    

 Good

Ref

 

Ref

 

 Intermediate

2.181 (1.416–3.361)

0.001

1.872 (1.326–2.642)

0.021

 Poor

4.005 (2.467–6.501)

0.001

2.574 (1.717–2.857)

0.008

  1. OS overall survival, PFS progression-free survival, HR hazard ratio, 95%CI 95% confidence interval, ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP a-fetoprotein, HBV hepatitis B virus, LIPI lung immune prognostic index